Search results
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
NBC New York· 3 days agoModerna and Merck said their experimental vaccine in combination with the therapy Keytruda improved survival and showed durable efficacy in a midstage study in patients with ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 5 days agoThe results showed a 12-month overall survival (“OS”) rate of 69%, a median overall survival (“mOS”) of 17.5 months, and a 30% overall ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 4 days agoJacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO PR Newswire BEIJING and SHANGHAI and CHICAGO, June 1, 2024 BEIJING and SHANGHAI and CHICAGO, June 1, 2024 /PRNewswire/ -- Jacobio Pharma ...
Lack of insurance may prevent Americans from accessing best cancer drugs
United Press International via Yahoo News· 3 days agoA cutting-edge class of drugs is saving and extending the lives of cancer patients. But the drugs,...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 4 days agoGenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024
ASCO24: Akeso’s bispecific vvonescimab faces a rocky road ahead in NSCLC
Pharmaceutical Technology via Yahoo Finance· 5 days agoBased on GlobalData’s NSCLC Epidemiology Forecast...more limited scope of first-line, metastatic...
...2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid...
Lake Arrowhead Mountain News· 5 days agoMore updated data from the Phase 1 study including in non-small cell lung cancer will be presented orally at the European Society for Medical Oncology ( ...
No Survival Advantage With Sacituzumab Over Chemo in Previously Treated NSCLC
MedPage Today· 4 days agoResults are 'disappointing as we need better therapies in the refractory space,' expert says
...Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage...
Digital Journal· 3 days agoAt a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis ...
... Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line...
Morningstar· 4 days agoGilead and Arcus Announce EtrumadenantPlus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer – In Cohort B of the ARC ...
